[Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
作者信息
Demina T L, Khachanova N V, Davydovskaia M V, Popova N F, Gusev E I
出版信息
Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):24-6.
PMID:18567192
Abstract
摘要
相似文献
1
[Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):24-6.
2
Efficacy and safety of prolonged immunomodulatory treatment with interferon beta.干扰素β长期免疫调节治疗的疗效与安全性。
Neurosci Behav Physiol. 2009 Jun;39(5):497-9. doi: 10.1007/s11055-009-9151-5.
3
[Interferons beta in patients with multiple sclerosis].[多发性硬化症患者中的β干扰素]
Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(7):54-5.
4
Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
Lancet. 2002 Nov 2;360(9343):1428; author reply 1428-9. doi: 10.1016/S0140-6736(02)11385-7.
5
[Interferon therapy of multiple sclerosis. A question of the correct dose?].[多发性硬化症的干扰素治疗。正确剂量的问题？]
Nervenarzt. 2001 Feb;72(2):67-8. doi: 10.1007/s001150050716.
6
Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis.早期大剂量注射β-1a干扰素治疗复发缓解型多发性硬化症的长期疗效
Clin Neurol Neurosurg. 2002 Jul;104(3):244-8. doi: 10.1016/s0303-8467(02)00046-x.
7
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.肌肉注射干扰素β-1a以及多发性硬化症不断发展的治疗选择和疗效评估：管理式医疗的考量
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S1-53. doi: 10.18553/jmcp.2013.19.s1.1.
8
Experiences with interferon-beta-1b treatment in MS after three year follow-up.三年随访后多发性硬化症患者使用β-1b干扰素治疗的经验。
Swiss Med Wkly. 2002 May 4;132(17-18):237. doi: 10.4414/smw.2002.09810.
9
Introduction.引言。
J Manag Care Pharm. 2013 Jan-Feb;19(1 Suppl A):S3. doi: 10.18553/jmcp.2013.19.s1.S03.
10
Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.中断治疗：针对多发性硬化症所开的β-干扰素的停药与换药
Neurology. 2003 Aug 26;61(4):551-4. doi: 10.1212/01.wnl.0000078885.05053.7d.
Zotero 插件